Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析

◆英語タイトル:Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH31043FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:66
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Lonza Group Ltd (LONN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lonza Group Ltd (Lonza) is a contract manufacturing and development solutions provider. The company offers services including, commercial mammalian and microbial manufacturing, clinical development and manufacturing. It also offers high potential active pharmaceutical ingredients, cell and gene therapy capabilities, advanced intermediates, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products. Lonza provides solutions for health and well-being, microbial and hygiene control, and composites and material protection. Lonza serves biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; formulators and service companies. The company operates manufacturing and R&D facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd Key Recent Developments

Feb 23,2021: Lonza is recognised by Ethisphere as one of the world’s most ethical companies 2021
Feb 16,2021: Lonza expands solid form services for small molecule drugs
Jan 28,2021: Lonza announces high-quality cryopreserved leukopaks for more flexibility in immunology and cell therapy research
Jan 27,2021: Lonza reports strong 2020 performance, driven by sales growth in pharma and biotech business
Jan 15,2021: Invitation to Lonza’s Full-Year Results 2020 Conference Call and Webcast

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Lonza Group Ltd – Key Facts
Lonza Group Ltd – Key Employees
Lonza Group Ltd – Key Employee Biographies
Lonza Group Ltd – Major Products and Services
Lonza Group Ltd – History
Lonza Group Ltd – Company Statement
Lonza Group Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Lonza Group Ltd – Business Description
Business Segment: Pharma Biotech & Nutrition
Overview
Performance
Business Segment: Specialty Ingredients
Overview
Performance
R&D Overview
Lonza Group Ltd – Corporate Strategy
Lonza Group Ltd – SWOT Analysis
SWOT Analysis – Overview
Lonza Group Ltd – Strengths
Lonza Group Ltd – Weaknesses
Lonza Group Ltd – Opportunities
Lonza Group Ltd – Threats
Lonza Group Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Lonza Group Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 23, 2021: Lonza is recognised by Ethisphere as one of the world’s most ethical companies 2021
Feb 16, 2021: Lonza expands solid form services for small molecule drugs
Jan 28, 2021: Lonza announces high-quality cryopreserved leukopaks for more flexibility in immunology and cell therapy research
Jan 27, 2021: Lonza reports strong 2020 performance, driven by sales growth in pharma and biotech business
Jan 15, 2021: Invitation to Lonza’s Full-Year Results 2020 Conference Call and Webcast
Jan 14, 2021: Cytiva delivers modular biologics factory to Lonza
Dec 21, 2020: Lonza Expands Conjugation Facility with Two Additional Manufacturing Suites
Dec 10, 2020: Lonza announces broad selection of high-resolution HLA-typed primary cell lots to support biologic drug research
Dec 09, 2020: Lovelace Biomedical provides research to find new formulation for lung cancer treatment
Dec 02, 2020: Lonza announces customer-dedicated suites for commercialization of bioconjugates
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Lonza Group Ltd, Key Facts
Lonza Group Ltd, Key Employees
Lonza Group Ltd, Key Employee Biographies
Lonza Group Ltd, Major Products and Services
Lonza Group Ltd, History
Lonza Group Ltd, Subsidiaries
Lonza Group Ltd, Joint Venture
Lonza Group Ltd, Key Competitors
Lonza Group Ltd, Ratios based on current share price
Lonza Group Ltd, Annual Ratios
Lonza Group Ltd, Annual Ratios (Cont...1)
Lonza Group Ltd, Annual Ratios (Cont...2)
Lonza Group Ltd, Interim Ratios
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Lonza Group Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fresenius SE & Co KGaA (FRE)-製薬・医療分野:企業M&A・提携分析
    Summary Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes mach …
  • Distell Group Limited:企業の戦略・SWOT・財務情報
    Distell Group Limited - Strategy, SWOT and Corporate Finance Report Summary Distell Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Quadrise Fuels International Plc (QFI):企業の財務・戦略的SWOT分析
    Quadrise Fuels International Plc (QFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • bioMerieux SA (BIM)-医療機器分野:企業M&A・提携分析
    Summary bioMerieux S.A. (bioMerieux) designs, develops and manufactures diagnostic systems and reagents for physicians and biologists. The company offers diagnostic solutions such as instruments, reagents and software. bioMerieux products are used diagnosing and managing infectious diseases, cardiov …
  • Keppel Corporation Limited:企業の戦略・SWOT・財務分析
    Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • JM AB:企業の戦略・SWOT・財務情報
    JM AB - Strategy, SWOT and Corporate Finance Report Summary JM AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Merit Medical Systems Inc (MMSI)-医療機器分野:企業M&A・提携分析
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …
  • YRC Worldwide Inc (YRCW):企業の財務・戦略的SWOT分析
    YRC Worldwide Inc (YRCW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SOM Biotech SL:製薬・医療:M&Aディール及び事業提携情報
    Summary SOM Biotech SL (SOM Biotech) is a drug repurposing company that discovers and develops new drugs for orphan indications. The company’s pipeline products include SOM0777, SOM0226, SOM3355, SOM1201 and SOM2201 are used for the treatment of TTR amyloidosis, glioblastoma, huntington disease, duc …
  • Curadev Pharma Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Curadev Pharma Pvt Ltd (Curadev Pharma) is a small molecule drug discovery company that manufactures, discovers, and delivers formulations. The company manufactures formulations and APIs such as cyclodextrin in collaboration with the University of Greenwich and creates and out-licenses pre-I …
  • CaroGen Corp-製薬・医療分野:企業M&A・提携分析
    Summary CaroGen Corp (CaroGen) is a vaccine company that offers platform technology development services. The company develops and commercializes nanoparticle therapeutic vaccines. It utilizes its virus-like vesicle platform technology, a proprietary replication competent to develop nano particle th …
  • PVR Ltd:企業のM&A・事業提携・投資動向
    PVR Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PVR Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Cloud Live Technology Group Co. Ltd.:企業の戦略・SWOT・財務分析
    Cloud Live Technology Group Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Cloud Live Technology Group Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Tactile Systems Technology Inc (TCMD):製品パイプライン分析
    Summary Tactile Systems Technology Inc (Tactile Medical) is a medical technology company that develops, manufactures and distributes medical devices for the treatment of chronic vascular diseases in a home setting. The company’s products are based on a unique, scalable platform. It offers products f …
  • Blackbird Energy Inc (BBI):企業の財務・戦略的SWOT分析
    Summary Blackbird Energy Inc (Blackbird Energy), formerly Blackbird Investments Inc, is an independent oil and gas exploration and development company that acquires, explores, produces and develops oil and gas properties in Western Canada. The company holds interests in Elmworth Project which concen …
  • Bayer AG:企業のM&A・事業提携・投資動向
    Bayer AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bayer AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • KCA Deutag Alpha Ltd:企業の戦略的SWOT分析
    KCA Deutag Alpha Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventiona …
  • Marinus Pharmaceuticals Inc (MRNS):製薬・医療:M&Aディール及び事業提携情報
    Summary Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA mod …
  • Itau Unibanco Holding SA:企業の戦略・SWOT・財務情報
    Itau Unibanco Holding SA - Strategy, SWOT and Corporate Finance Report Summary Itau Unibanco Holding SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆